Skip to main content

AmoyDx, Medikonia Ink MDx Distribution Deal

NEW YORK (GenomeWeb) – Medikonia said today it has inked a distribution agreement to make Amoy Diagnostics' range of molecular diagnostic tests available in Hong Kong and Macau.

Additional terms of the agreement were not disclosed.

Pau Huang, AmoyDx's international sales and marketing director, said in a statement that the firm's molecular diagnostic tests, which are powered by its proprietary PCR-based ADx Amplification Refractory Mutation System (ADx-ARMS) and Super-ARMS technologies, help patients receive the correct cancer drugs.

Last week, AmoyDx said that the China Food and Drug Administration approved its Super-ARMS EGFR mutation analysis test as a companion diagnostic for EGFR TKI-based non-small cell lung cancer drugs. The Super-ARMS EGFR kit is a PCR-based test which is designed to identify EGFR mutations in circulating tumor DNA from plasma samples for patients with advanced or metastatic non-small cell lung cancer, according to the firm's website.